| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEWS |
From the Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.
Address reprint requests to: Robert L. Barbieri, MD, Brigham and Women’s Hospital, Harvard Medical School, Department of Obstetrics and Gynecology, 75 Francis Street, Boston, MA 02115; E-mail: rbarbieri{at}partners.org.
OBJECTIVE: To familiarize obstetrician–gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS).
DATA SOURCES: Using OVID, 94 English-language articles published after 1966 indexed with the key words "metformin" and "polycystic ovary syndrome" were identified.
METHODS OF STUDY SELECTION: Studies were excluded if they did not have a control group, did not use the National Institutes of Health definition of PCOS, did not have a clinical outcome as an end point, and were not in the English language. Reviews were also excluded, leaving 21 articles for inclusion.
TABULATION, INTEGRATION, AND RESULTS: Three clinical trials reported that for the treatment of anovulatory infertility caused by PCOS, metformin plus clomiphene is more effective than clomiphene alone in inducing ovulation. For the treatment of irregular menses caused by PCOS in women not attempting conception, metformin therapy may restore ovulatory menses in the majority of women. However, most women will require 4–6 months of metformin therapy before they achieve ovulatory menses. In obese women, metformin plus a low-calorie diet may be associated with more weight loss than a low-calorie diet alone.
CONCLUSION: Polycystic ovary syndrome is a common gynecologic endocrine disorder. Obstetrician–gynecologists should be familiar with the indications and contraindications for the use of metformin in their practice.
This article has been cited by other articles:
|
|
 |
|
  R. L. Rosenfield Identifying Children at Risk for Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gennarelli, V. Rovei, R. F. Novi, J. Holte, F. Bongioanni, A. Revelli, G. Pacini, P. Cavallo-Perin, and M. Massobrio Preserved Insulin Sensitivity and {beta}-Cell Activity, but Decreased Glucose Effectiveness in Normal-Weight Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3381 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Le Du, I.J. Kadoch, N. Bourcigaux, S. Doumerc, M-C. Bourrier, N. Chevalier, R. Fanchin, R-C. Chian, G. Tachdjian, R. Frydman, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience Hum. Reprod., February 1, 2005; 20(2): 420 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ombelet, P. De Sutter, J. Van der Elst, and G. Martens Multiple gestation and infertility treatment: registration, reflection and reaction--the Belgian project Hum. Reprod. Update, January 1, 2005; 11(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Legro, E. Myers, and for the Reproductive Medicine Network Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
